<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642924</url>
  </required_header>
  <id_info>
    <org_study_id>L19-069</org_study_id>
    <nct_id>NCT04642924</nct_id>
  </id_info>
  <brief_title>SGM-101 in Locally Advanced and Recurrent Rectal Cancer</brief_title>
  <acronym>SGM-LARRC</acronym>
  <official_title>Multicenter, Open-label, Controlled, Parallel Arms Clinical Study on the Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen (CEA) Monoclonal Antibody, for Locally Advanced or Recurrent Rectal Cancer Patients Undergoing Curative Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center Haaglanden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Surgimab</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quest Medical Imaging</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Human Drug Research, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Near-infrared fluorescence-guided oncologic surgery (EGOS) with the use of a tumor specific&#xD;
      tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about&#xD;
      tumor location and extensiveness, which can be difficult to detect with conventional visual&#xD;
      and tactile feedback. Hence, this information could aid in intra-operative decision making&#xD;
      and therewith foster complete resection margins and less extensive surgery. Subsequently,&#xD;
      this may drastically improve patient care by improving oncologic outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospectively inclusion treatment arm. Compared to historical cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resection status</measure>
    <time_frame>10 days post surgery</time_frame>
    <description>Pathologic resection status (R0 or R1)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">203</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Locally Advanced Rectal Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients included with locally advanced rectal cancer SGM-101 10mg, 3-5 days prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recurrent rectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients included with (locally) recurrent rectal cancer SGM-101 10mg, 3-5 days prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGM-101</intervention_name>
    <description>Fluorescence-guided surgery</description>
    <arm_group_label>Locally Advanced Rectal Cancer</arm_group_label>
    <arm_group_label>Recurrent rectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged over 18 years old;&#xD;
&#xD;
          2. All women of child bearing potential and all males must practice effective&#xD;
             contraception during the study and be willing and able to continue contraception for&#xD;
             at least 30 days after their last dose of study treatment.&#xD;
&#xD;
          3. Patients should be scheduled and eligible for surgery because of a clinical diagnosis&#xD;
             of T3 with a threatened CRM or T4 rectal cancer (locally advanced) or recurrent rectal&#xD;
             cancer. (UICC. TNM classification of diseases for oncology. 3rd ed. Geneva: World&#xD;
             Health Organization; 2000)&#xD;
&#xD;
          4. Patients should be capable and willing to give signed informed consent before study&#xD;
             specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other malignancies, either currently or in the past five years, except adequately&#xD;
             treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma.&#xD;
&#xD;
          2. Patients with a history of, or recently diagnosed with, peritoneal metastases (even&#xD;
             those diagnosed during surgery)&#xD;
&#xD;
          3. Patients with a recent history (within the last 3 years) of other distant metastases&#xD;
             (even those diagnosed during surgery)&#xD;
&#xD;
          4. Patient with a history of a clinically significant allergy.&#xD;
&#xD;
          5. Patients pregnant or breastfeeding lack of effective contraception in male or female&#xD;
             patients with reproductive potential;&#xD;
&#xD;
          6. Laboratory abnormalities defined as:&#xD;
&#xD;
               1. Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase)&#xD;
                  or Alkaline Phosphatase levels above 5 times the or;&#xD;
&#xD;
               2. Total bilirubin above 2 times the ULN or;&#xD;
&#xD;
               3. Serum creatinine above 1.5 times the ULN or;&#xD;
&#xD;
               4. Platelet count below 100 x 109/L or;&#xD;
&#xD;
               5. Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);&#xD;
&#xD;
               6. Known positive test for human immunodeficiency virus (HIV), hepatitis B surface&#xD;
                  antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated&#xD;
                  serious infections;&#xD;
&#xD;
          7. Any condition that the investigator considers to be potentially jeopardizing the&#xD;
             patients' well-being or the study objectives.&#xD;
&#xD;
          8. Previous administration of SGM-101&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruben Meijer</last_name>
    <phone>+31 71-52 98420</phone>
    <email>r.p.j.meijer@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miranda Kusters</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medisch Centrum</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Marinelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harm Rutten</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kees Verhoef</last_name>
      <phone>+31 10 704 0704</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Alexander Vahrmeijer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

